Navigation Links
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
Date:3/12/2009

CHADDS FORD, Pa., March 12 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) and its majority-owned subsidiary Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the complete response submission to the new drug application for NEBIDO(R) (testosterone undecanoate) intramuscular injection, an investigational testosterone preparation for the treatment of male hypogonadism. FDA is targeting September 2, 2009 as the action date for a decision on this application.

Endo's president and CEO, David Holveck, stated: "We are pleased with the FDA's action and congratulate the NEBIDO development team on reaching this milestone. We look forward to receiving the FDA's decision on the NEBIDO marketing application in September."

About NEBIDO

NEBIDO is a novel, long-acting injectable testosterone preparation for the treatment of male hypogonadism. NEBIDO was licensed by BayerSchering Pharma AG to Indevus Pharmaceuticals, a majority interest in which Endo acquired earlier this year. If approved, NEBIDO is expected to be the first long-acting testosterone preparation available in the U.S. in the growing market for testosterone replacement therapies. NEBIDO is currently marketed by BayerSchering and its partners in Europe and other territories.

About Hypogonadism

Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Reduced testosterone levels can lead to health problems and significantly impair quality of life. Common effects of hypogonadism include decreased sexual desire, erectile dysfunction, musc
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
2. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)... BOTHELL, Wash. , Oct. 30, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s third quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... TUSTIN, Calif., Jan. 6, 2012 Radient Pharmaceuticals Corporation ... Vitro Diagnostic (IVD) cancer tests, today announced that ... will be launched with a print ad that ... throughout 2012.  These journals have high circulation among ...
... WAYNE, N.J., Jan. 6, 2012  Cascade Medical ... proprietary platelet-rich plasma (PRP) and platelet-rich fibrin matrix (PRFM) ... tissue and bone repair, announced the sale of their ... ConMed Linvatec for the worldwide orthopedic, dental, and wound ...
Cached Medicine Technology:Radient Pharmaceuticals Announces New Advertisement for Oncology Publications 2Cascade Medical Enterprises, LLC Announces the Sale of Their Orthopedic Business 2
(Date:10/30/2014)... 30, 2014 Five months after their ... Street LLC announces new branding and a website to ... . After David Mepham’s promotion to name partner earlier ... website to include Mepham’s name and better reflect their ... mediation firm, the decision to implement new branding reflects ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits manager ... help people save money through its innovative discount card ... drugs in the new health care system, the Paramount ... the relationship between consumers, businesses and the pharmacy industry. ... face today with medical costs is the rising price ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... in Liberia -- one of three West African nations ravaged ... officials said Wednesday. Dr. Bruce Aylward, WHO,s assistant director ... burials in Liberia and no increase in laboratory-confirmed cases. He ... tame the epidemic may be making some progress, The ...
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2
... Advisors Transitioning to Independence, SAN FRANCISCO, ... new relationship with national human resources,outsourcing company ... for,independent investment advisors and their employees. As ... advisors who custody,assets with Schwab will now ...
... 15 Dong-A PharmTech Co. Ltd,announced today the signing ... to market in Russia Dong-A,s erectile,dysfunction drug which is ... Under the terms of the agreement, Otechestvennye Lekarstva ... both upfront fees and,running royalty on sales for the ...
... as well, 266,604 fewer patients would die annually, survey ... in the top-ranked hospitals in the United States are ... the lowest-rated hospitals, according to a new study from ... HealthGrades Hospital Quality in America Study looked at 41 ...
... scientists this month joined Biomoda, Inc. (OTC Bulletin ... assist with,commercialization efforts of the company,s early lung ... "Constance Dorian brings strong analytical skills and significant,understanding ... She will be an important asset in all ...
... Researchers and Health Professionals Gather at Mental ... November 2nd, NEW YORK, Oct. 15 In ... Long Island Mental Illness,Awareness Day presented by Clubhouse of ... at the Huntington Hilton in Melville, NY from 8:00,AM ...
... fifth of patients need to work through mental problems ... -- About one in every five people who were ... recommended psychiatric clearance for the procedure, a U.S. study ... screening process in most bariatric surgery programs, notes a ...
Cached Medicine News:Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 2Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 3Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 4Health News:Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia 2Health News:America's Top Hospitals Are Real Lifesavers 2Health News:Two Scientists Join Team of Biomoda, Inc. 2Health News:Clubhouse of Suffolk to Host 15th Annual Mental Illness Awareness Day 2Health News:Psychiatric Woes Can Postpone Weight-Loss Surgery 2
Stainless steel plain Steinman Pins available in point types A through F....
Full pin skeletal traction pins with cove point....
Calibrated Guide Pins have a 12.7 mm calibration and are available in plain, with a threaded tip, or with a trocar point....
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
Medicine Products: